Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Noguchi Institute currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is managed by 1 distinct examiner and 1 distinct art unit, suggesting that the institute's current patent prosecution is limited to a single specific application. The data indicates that the institute is not currently diversifying its filings across multiple examiners or departments. Practitioners should recognize that the 1 distinct art unit involved will define the procedural standards for the entirety of the active portfolio.
The busiest examiner, CHANDRAKUMAR, NIZAL S, is responsible for 1 busiest examiner pending office action. Because the total pending office actions count is 1, this examiner is the sole official reviewing the institute's active filings. The involvement of 1 distinct examiner further indicates a concentrated administrative path. For practitioners, the 1 busiest examiner pending office action is the only active matter in the portfolio, meaning that the current prosecution strategy is entirely focused on the interactions with this single examiner within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17907119 | SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX | CHANDRAKUMAR, NIZAL S | 57d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17907119 | SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX | CHANDRAKUMAR, NIZAL S | 57d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17907119 | SUGAR COMPOUND HAVING POLYETHYLENE GLYCOL CHAIN, AND PRECURSOR OF ANTIBODY-DRUG COMPLEX | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Final Rejection | 57d | Pending | Nov 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial